358 related articles for article (PubMed ID: 22073939)
1. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
Coleman CI; Sobieraj DM; Marinucci LN
Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
4. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
5. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
Hobart J; Blight AR; Goodman A; Lynn F; Putzki N
Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489
[TBL] [Abstract][Full Text] [Related]
6. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
[TBL] [Abstract][Full Text] [Related]
7. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
[TBL] [Abstract][Full Text] [Related]
8. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
9. A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients.
Phan-Ba R; Calay P; Grodent P; Delrue G; Lommers E; Delvaux V; Moonen G; Nagels G; Belachew S
NeuroRehabilitation; 2012; 30(4):261-6. PubMed ID: 22672939
[TBL] [Abstract][Full Text] [Related]
10. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
Mathiesen HK; Sorensen PS
Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
[TBL] [Abstract][Full Text] [Related]
11. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
12. Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM; Keating GM
CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
[TBL] [Abstract][Full Text] [Related]
13. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
[TBL] [Abstract][Full Text] [Related]
15. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
[TBL] [Abstract][Full Text] [Related]
16. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight AR; Henney HR; Cohen R
Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.
Phan-Ba R; Pace A; Calay P; Grodent P; Douchamps F; Hyde R; Hotermans C; Delvaux V; Hansen I; Moonen G; Belachew S
Neurorehabil Neural Repair; 2011 Sep; 25(7):672-9. PubMed ID: 21436388
[TBL] [Abstract][Full Text] [Related]
18. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
[TBL] [Abstract][Full Text] [Related]
19. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
[TBL] [Abstract][Full Text] [Related]
20. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
